Credit Suisse’s Aprea Therapeutics APRE Stock Holding History

Credit Suisse’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,699	Closed	-$167K	–	4282
2020 Q4	$167K	Buy	1,699 +1,135	+201%	+$540K	﹤0.01%	4122
2020 Q3	$270K	Buy	+564	New	+$316K	﹤0.01%	3704
2020 Q2	–	Sell	-1,404	Closed	-$977K	–	3943
2020 Q1	$977K	Buy	+1,404	New	+$1.03M	﹤0.01%	2658

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Credit Suisse's APRE Position: Q1 2021 in Review

Credit Suisse sold out of Aprea Therapeutics (APRE) in Q1 2021, closing a stake of 1,699 shares — an estimated $167K sold.

Credit Suisse first reported a position in APRE in Q1 2020 and held it in 3 quarters. The position peaked at $977K in Q1 2020. 67 funds tracked by Wall St. Rank hold APRE as of Q1 2021.

Credit Suisse reported no remaining Aprea Therapeutics position as of Q1 2021 after selling out during the quarter.
Credit Suisse sold 1,699 Aprea Therapeutics shares in Q1 2021, an estimated $167K.
Credit Suisse first reported a position in Aprea Therapeutics in Q1 2020 and held it in 3 quarters.
Credit Suisse's Aprea Therapeutics position peaked at $977K in Q1 2020.
67 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.